Efficacy of rituximab in patients with rheumatoid arthritis refractory or with contra-indication to anti-tumor necrosis factor-alpha drugs in daily practice: An open label observational study [3]
ADULT;
CONTROLLED STUDY;
DRUG CONTRAINDICATION;
DRUG EFFICACY;
DRUG RESPONSE;
DRUG SAFETY;
DRUG TOLERABILITY;
HUMAN;
INJECTION SITE REACTION;
LETTER;
LUNG INFECTION;
OBSERVATIONAL STUDY;
OPEN STUDY;
OUTCOME ASSESSMENT;
PATIENT SELECTION;
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial
EMERY P, FLEISCHMANN R, FILIPOWICZ-SOSNOWSKA A et al.: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390-400.
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
EDWARDS JC, SZCZEPANSKI L, SZECHINSKI et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81.
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
COHEN SB, EMERY P, GREENWALD MW et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment
HIGASHIDA J, WUN T, SCHMIDT S et al.: Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. J Rheumatol 2005; 32: 2109-15.
Efficacy of B-cell Depletion in Rheumatoid Arthritis Patients Refractory to Anti-Tumour Necrosis factor (TNF)-α Agents An open label observational study
Mar 15; [Epub ahead of print
BRULHART L, CIUREA A, FINCKH A et al.: Efficacy of B-cell Depletion in Rheumatoid Arthritis Patients Refractory to Anti-Tumour Necrosis factor (TNF)-α Agents An open label observational study. Ann Rheum Dis 2006 Mar 15; [Epub ahead of print].
